Surveillance of antimicrobial resistance in Streptococcus agalactiae isolated from pregnant women and newborns in 2010–2022 | CMAC

Surveillance of antimicrobial resistance in Streptococcus agalactiae isolated from pregnant women and newborns in 2010–2022

Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):194-200

​ Khusnutdinova T.A., Shalepo K.V., Budilovskaya O.V., Krysanova A.A., Spasibova E.V., Sinyakova A.A., Tapilskaya N.I., Savicheva A.M., Kogan I.Yu.
10.36488/cmac.2024.2.194-200
Streptococcus agalactiae antimicrobial resistance resistance genes
Section
Antimicrobial Resistance
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):194-200

Objective.

To study the dynamics and molecular mechanisms of resistance of Streptococcus agalactiae strains isolated from pregnant women and newborns in St. Petersburg in 2010–2022.

Materials and Methods.

The strains of S. agalactiae (n = 248) were obtained by analyzing the clinical material of pregnant women and newborns who were hospitalized at Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott in 2010–2011 and 2020–2022. Determination of susceptibility to antibacterial drugs was evaluated by disk diffusion method. The detection of resistance genes to macrolides and lincosamides (mef and ermB) was performed by real-time PCR using reagents «Resistom MLSB-Streptococcus» (Litech, Russia).

Results.

All isolates S. agalactiae (n = 248) were sensitive to penicillin and vancomycin. Compared to 2010–2011, the resistance of S. agalactiae to erythromycin increased from 18.4% to 42.1% and to clindamycin from 15.6% to 39.3%. Among S. agalactiae strains (n = 71) resistant to erythromycin and clindamycin, cMLSB phenotype was predominant (59.1%); iMLSB (31%) and M-phenotype (9.9%) were less common. The results of detection of genes encoding resistance to erythromycin and clindamycin showed that in 38 (53.5%) and 9 (12.7%) isolates of S. agalactiae resistance genes ermB and mefA were detected as one resistance determinant, respectively, association of two ermB/mefA genes was detected in 2 (2.8%) strains; resistance genes were not detected in 22 (31%) isolates.

Conclusions.

Penicillin and vancomycin are effective drugs for the treatment and prevention of infections caused by S. agalactiae. The increase in resistance to macrolides and lincosamides reflects the global trend of increasing resistance to these antibiotics. Regular monitoring of antibiotic resistance of the pathogen is necessary to update the clinical recommendations.

Tatiana A. Khusnutdinova

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Shalepo K.V.

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Budilovskaya O.V.

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Krysanova A.A.

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Spasibova E.V.

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Sinyakova A.A.

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Tapilskaya N.I.

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Alevtina M. Savicheva

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

Kogan I.Yu.

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia

  • 1. Gonçalves B.P., Procter S.R., Paul P., Chandna J., Lewin A., Seedat F., et al. Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden. Lancet Glob Health. 2022;10(6):e807-e819. DOI: 10.1016/S2214-109X(22)00093-6
  • 2. Hanna M., Noor A. Streptococcus Group B. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021.
  • 3. Huang J., Li S., Li L., Wang X., Yao Z., Ye X. Alarming regional differences in prevalence and antimicrobial susceptibility of group B streptococci in pregnant women: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2016;7:169-177. DOI: 10.1016/j.jgar.2016.08.010
  • 4. LLC "Russian Society of Obstetricians and Gynecologists" (ROAG). Clinical Recommendations "Normal Pregnancy", 2020. Russian.
  • 5. Lu B., Chen X., Wang J., Wang D., Zeng J., Li Y., et al. Molecular characteristics and antimicrobial resistance in invasive and noninvasive Group B Streptococcus between 2008 and 2015 in China. Diagn Microbiol Infect Dis. 2016;86(4):351-357. DOI: 10.1016/j.diagmicrobio.2016.08.023
  • 6. Khademi F., Sahebkar A. Group B streptococcus drug resistance in pregnant women in Iran: a meta-analysis. Taiwan J Obstet Gynecol. 2020;59(5):635-642. DOI: 10.1016/j.tjog.2020.07.002
  • 7. Sabroske E.M., Iglesias M.A.S., Rench M., Moore T., Harvey H., Edwards M., et al. Evolving antibiotic resistance in Group B streptococci causing invasive infant disease: 1970-2021. Pediatr Res. 2023;93(7):2067-2071. DOI: 10.1038/s41390-022-02375-3
  • 8. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482492. DOI: 10.1086/324626
  • 9. Egorov A. M., Ulyashova M.M., Rubcova M.Yu. Bacterial enzymes and antibiotic resistance. Acta Naturae. 2018;10(4)33-48. Russian.
  • 10. Russian clinical guidelines «Susceptibility testing of microorganisms to antimicrobial drugs «Version 202101. Available at: www.antibiotic.ru/minzdrav/files/docs/clrec-dsma.2021.pdf. Accessed August 2022. Russian.
  • 11. Nanduri S.A., Petit S., Smelser C., Apostol M., Alden N.B., Harrison L.H., et al. Epidemiology of invasive early-onset and late-onset group b streptococcal disease in the United States, 2006 to 2015: multistate laboratory and populationbased surveillance. JAMA Pediatr. 2019;173(3):224233. DOI: 10.1001/jamapediatrics.2018.4826
  • 12. O’Sullivan C.P., Lamagni T., Patel D., Efstratiou A., Cunney R., Meehan M., et al. Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014-15: a prospective surveillance study. Lancet Infect Dis. 2019;19(1):83-90. DOI: 10.1016/S14733099(18)30555-3
  • 13. Kimura K., Suzuki S., Wachino J., Kurokawa H., Yamane K., Shibata N., et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother. 2008;52(8):2890-2897. DOI: 10.1128/AAC.00185-08
  • 14. Dahesh S., Hensler M.E., Van Sorge N.M., Gertz R.E., Schrag S., Nizet V., et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother. 2008;52(8):2915-2918. DOI: 10.1128/AAC.00461-08
  • 15. Metcalf B.J., Chochua S., Gertz R.E., Hawkins P.A., Ricaldi J., Li Z., et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA. Clin Microbiol Infect. 2017;23(8):574.e7-574.e14. DOI: 10.1016/j.cmi.2017.02.021
  • 16. Yi A., Kim C.K., Kimura K., Arakawa Y., Hur M., Yun Y.M., et al. First case in Korea of group B Streptococcus with reduced penicillin susceptibility harboring amino acid substitutions in penicillin-binding protein 2X. Ann Lab Med. 2019;39(4):414-416. DOI: 10.3343/alm.2019.39.4.414
  • 17. Genovese C., D'Angeli F., Di Salvatore V., Tempera G., Nicolosi D. Streptococcus agalactiae in pregnant women: serotype and antimicrobial susceptibility patterns over five years in Eastern Sicily (Italy). Eur J Clin Microbiol Infect Dis. 2020;39(12):2387-2396. DOI: 10.1007/s10096-02003992-8
  • 18. Hayes K., O'Halloran F., Cotter L. A review of antibiotic resistance in Group B Streptococcus: the story so far. Crit Rev Microbiol. 2020;46(3):253-269. DOI: 10.1080/1040841X.2020.1758626
  • 19. Shipitsyna E., Shalepo K., Zatsiorskaya S., Krysanova A., Razinkova M., Grigoriev A., Savicheva A. Significant shifts in the distribution of vaccine capsular polysaccharide types and rates of antimicrobial resistance of perinatal group B streptococci within the last decade in St. Petersburg, Russia. Eur J Clin Microbiol Infect Dis. 2020;39(8):14871493. DOI: 10.1007/s10096-020-03864-1
  • 20. Priputnevich T.V., Lyubasovskaya L.A., SHuvalova M.P., Bajbarina E.N., Suhih G.T. Healthcare-associated infections (HAI) in maternity hospitals of Russian Federation (the state of the problem at the beginning of the XXI century) Vestnik RAMN. 2021;76(2):133-141. Russian. DOI: 10.15690/vramn1523
  • 21. Verani J.R., McGee L., Schrag S.J. Division of bacterial diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease – revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1-36. PMID: 21088663.
  • 22. Capanna F., Emonet S.P., Cherkaoui A., Irion O., Schrenzel J., Martinez de Tejada B. Antibiotic resistance patterns among group B Streptococcus isolates: implications for antibiotic prophylaxis for early-onset neonatal sepsis. Swiss Med Wkly. 2013;143:w13778. DOI: 10.4414/smw.2013.13778
  • 23. Motallebirad T., Fazeli H., Ghahiri A., Shokri D., Jalalifar S., Moghim S., et al. Prevalence, population structure, distribution of serotypes, pilus islands and resistance genes among erythromycin-resistant colonizing and invasive Streptococcus agalactiae isolates recovered from pregnant and non-pregnant women in Isfahan, Iran. BMC Microbiol. 2021;21(1):139. DOI: 10.1186/s12866-021-02186-2
  • 24. Bergal A., Loucif L., Benouareth D.E., Bentorki A.A., Abat C., Rolain J.M. Molecular epidemiology and distribution of serotypes, genotypes, and antibiotic resistance genes of Streptococcus agalactiae clinical isolates from Guelma, Algeria and Marseille, France. Eur J Clin Microbiol Infect Dis. 2015;34(12):2339-2348. DOI: 10.1007/s10096-015-2487-6
  • 25. Back E.E., O'Grady E.J., Back J.D. High rates of perinatal group B Streptococcus clindamycin and erythromycin resistance in an upstate New York hospital. Antimicrob Agents Chemother. 2012;56(2):739-742. DOI: 10.1128/AAC.05794-11
  • 26. Teatero S., Ferrieri P., Martin I., Demczuk W., McGeer A., Fittipaldi N. Serotype distribution, population structure, and antimicrobial resistance of group B streptococcus strains recovered from colonized pregnant women. J Clin Microbiol. 2017;55(2):412-422. DOI: 10.1128/JCM.01615-16
Views
0 Abstract
0 PDF
0 Crossref citations
Shared